Ceftolozan / Tazobactam (6) (Zerbaxa®) – Bacterial infections, multiple indications

Characteristics

Start date 01.05.2022
Resolution 03.11.2022
INN Ceftolozan / Tazobactam
Brand name Zerbaxa®
Pharm. company MSD Sharp & Dohme GmbH
G-BA procedure ID 2022-05-01-D-815
ATC code J01DI54
Therapeutic area Infectious diseases
Reason for procedure Initial assessment – Reserve antibiotic
Regulatory status Reserve antibiotic

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Zerbaxa is indicated for the treatment of the following infections in adult and pediatric patients:

Complicated intra-abdominal infections;

Acute pyelonephritis;

Complicated urinary tract infections.

Zerbaxa is also indicated in adults for the treatment of the following infection in adult patients (18 years of age and older):

Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).

Subpopulation Indication Comparator
a)
b) Adults with acute pyelonephritis
c) Adults with complicated urinary tract infection
d) Adults with hospital-acquired pneumonia, including ventilator-associated pneumonia

9. Associated procedures



<< List of all resolutions

Log in to read more ...

The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.